# Denileukin PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/denileukin

> The FDA approved denileukin, sponsored by CITIUS ONCOLOGY, INC. (CTOR), on Dec 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | denileukin |
| Codes |  |
| Sponsor | CITIUS ONCOLOGY, INC. (CTOR) https://sec-api.dev/companies/ctor/catalysts |
| Indications | [high risk relapsed or refractory diffuse large b cell lymphoma](https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma), [high-risk relapsed or refractory diffuse large b-cell lymphoma](https://sec-api.dev/indications/high-risk-relapsed-or-refractory-diffuse-large-b-cell-lymphoma) |
| Modality |  |
| FDA designations | accelerated |

## Timeline

### Aug 2024: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-06-17, last confirmed 2025-12-01.
- Press release filed with the SEC (EX-99) (accession 0001213900-25-116764): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025116764/ea026756001ex99-2_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-055182): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1851484/000121390025055182/ea024593301ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-25-116760): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA in August 2024." https://www.sec.gov/Archives/edgar/data/1506251/000121390025116760/ea026756201ex99-2_citius.htm

### Dec 2025: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2026-03-04, last confirmed 2026-06-01.
- Press release filed with the SEC (EX-99) (accession 0001213900-26-063530): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026063530/ea029290301ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-052552): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026052552/ea028929701ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-049347): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026049347/ea028820201ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-037501): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026037501/ea028432101ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025464): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea028066301ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023440): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea027742301ex99-1_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-049338): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026049338/ea028820301ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-037524): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026037524/ea028432301ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-025459): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026025459/ea028066401ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023439): "LYMPHIR (denileukin diftitox-cxdl) was approved by the FDA and subsequently launched in the U.S. in December 2025." https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea027742201ex99-1_citius.htm

### March 4, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 1. Indication: high risk relapsed or refractory diffuse large B cell lymphoma.
- First seen 2026-03-04, last confirmed 2026-03-04.
- SEC Form 8-K (accession 0001213900-26-023440): "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023440): "(Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox-cxdl) administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea027742301ex99-1_citius.htm
- SEC Form 8-K (accession 0001213900-26-023439): "March 4, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea0277422-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023439): "N.J., March 4, 2026 - Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox-cxdl)" https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea027742201ex99-1_citius.htm

### March 4, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1. Indication: high risk relapsed or refractory diffuse large B cell lymphoma.
- First seen 2026-03-04, last confirmed 2026-03-04.
- SEC Form 8-K (accession 0001213900-26-023440): "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023440): "(Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox-cxdl) administered prior to commercial CD19-directed CAR-T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea027742301ex99-1_citius.htm
- SEC Form 8-K (accession 0001213900-26-023439): "March 4, 2026, Citius Oncology, Inc. (Nasdaq: CTOR), our majority-owned subsidiary, issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea0277422-8k_citius.htm
- Press release filed with the SEC (EX-99) (accession 0001213900-26-023439): "N.J., March 4, 2026 - Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox-cxdl)" https://www.sec.gov/Archives/edgar/data/1506251/000121390026023439/ea027742201ex99-1_citius.htm

## Same indication

- [LYMPHIR (lymphir)](https://sec-api.dev/pdufa/lymphir) (CTOR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/denileukin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Denileukin PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/denileukin

```bibtex
@misc{secapidev_pdufa_denileukin_20261116,
  title        = {Denileukin PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/denileukin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_denileukin_20261116","title":"Denileukin PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/denileukin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
